Linked Life Data

9769622

Source:http://linkedlifedata.com/resource/pubmed/id/9769622

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1998-11-24
pubmed:abstractText
Major depressive disorder in 26 hospice inpatients was managed with a trial of methylphenidate (mean daily dosage, 17.7 mg). A therapeutic response was achieved in 46% of the sample. However, a significant response was obtained in only 7% of those patients who subsequently died of their terminal illness within 6 weeks. Higher dosage psychostimulants may be indicated in the last weeks of life of the terminally ill. Alternatively "vital exhaustion" may account for the poor response rate in the treatment of depression in patients with advanced malignancy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0885-3924
pubmed:author
pubmed:issnType
Print
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
193-8
pubmed:dateRevised
2006-8-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Methylphenidate in terminal depression.
pubmed:affiliation
Department of Psychological Medicine, Christchurch School of Medicine, New Zealand.
pubmed:publicationType
Journal Article, Clinical Trial